Tech Company Financing Transactions

BioVex Funding Round

BioVex closed a $40 million Series F financing round on 3/30/2009. Investors included Forbion Capital Partners, Harris & Harris Group and Innoven Partners.

Transaction Overview

Company Name
BioVex
Announced On
3/30/2009
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series F
Investors

Forbion Capital Partners (Lead Investor)

Harris & Harris Group (Misti Ushio)

Innoven Partners

New Science Ventures (Somu Subramaniam)

Scottish Equity Partners (Brian Kerr)

Triathlon Medical Ventures (Suzette Dutch)

Proceeds Purpose
Following the unprecedented number of durable complete remissions generated with our lead cancer product, OncoVEX GM-CSF in a Phase II study in metastatic melanoma, the funds will be used to commence a pivotal Phase III study.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
34 Commerce Way
Woburn, MA 01801
USA
Phone
(781) 376-4900
Website
www.biovex.com
Email Address
[email protected]
Overview
The Company is developing a new class of potent biologics for the treatmentof cancer and prevention of infectious disease.
Profile
BioVex LinkedIn Company Profile
Social Media
BioVex Company Twitter Account
Company News
BioVex News
Facebook
BioVex on Facebook
YouTube
BioVex on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Philip Astley-Sparke
  Philip Astley-Sparke LinkedIn Profile  Philip Astley-Sparke Twitter Account  Philip Astley-Sparke News  Philip Astley-Sparke on Facebook
Chief Financial Officer
Stephen Gorgol
  Stephen Gorgol LinkedIn Profile  Stephen Gorgol Twitter Account  Stephen Gorgol News  Stephen Gorgol on Facebook
Chief Medical Officer
Howard Goldsweig
  Howard Goldsweig LinkedIn Profile  Howard Goldsweig Twitter Account  Howard Goldsweig News  Howard Goldsweig on Facebook
Chief Technical Officer
Robert Coffin
  Robert Coffin LinkedIn Profile  Robert Coffin Twitter Account  Robert Coffin News  Robert Coffin on Facebook
VP - Bus. Development
Pamela Esposito
  Pamela Esposito LinkedIn Profile  Pamela Esposito Twitter Account  Pamela Esposito News  Pamela Esposito on Facebook
VP - Manufacturing
Paul Bullock
  Paul Bullock LinkedIn Profile  Paul Bullock Twitter Account  Paul Bullock News  Paul Bullock on Facebook
VP - Operations
Timothy Hanke
  Timothy Hanke LinkedIn Profile  Timothy Hanke Twitter Account  Timothy Hanke News  Timothy Hanke on Facebook
VP - Operations
Lance Weed
  Lance Weed LinkedIn Profile  Lance Weed Twitter Account  Lance Weed News  Lance Weed on Facebook
VP - Product Management
Colin Love
  Colin Love LinkedIn Profile  Colin Love Twitter Account  Colin Love News  Colin Love on Facebook
VP - Regulatory Affairs
Anne Woodland
  Anne Woodland LinkedIn Profile  Anne Woodland Twitter Account  Anne Woodland News  Anne Woodland on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/30/2009: TargAnox venture capital transaction
Next: 3/30/2009: Sutro Biopharma venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

Our team works diligently to record every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.